MNTA: Momenta Pharmaceuticals Inc. is a Sell

The current rating for MNTA is 32, which is 56% below its historic median rating of 50. This indicates higher risk than normal.

The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.